Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient's own, small dataset to dynamically personalize only their own dose recommendations. The primary objective of this feasibility trial was to assess the logistical and scientific feasibility of providing dynamically personalized AI-derived chemotherapy dose recommendations for patients with advanced solid tumors at/for treatment with single-agent capecitabine, capecitabine in combination with oxaliplatin (XELOX), or capecitabine in combination with irinotecan (XELIRI). CURATE.AI demonstrated adaptability to clinically relevant situations encountered by patients often treated with palliative intent of care. High rates of user adherence were demonstrated, which could be in part due to the high engagement of the physicians in selecting data and boundaries for CURATE.AI operations.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2025-02-21
DOI
https://doi.org/10.1038/s41698-025-00835-7
Citations
12
Primary Topic
Advanced Radiotherapy Techniques
Type
article
Field-Weighted Citation Impact
22.59

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Shi‐Bei Tan, Wei Peng Yong, Dean Ho, Xavier Tadeo et al.
12 citations
npj Precision Oncology
Advanced Radiotherapy Techniques
22.59
article

Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Shi‐Bei Tan, Wei Peng Yong, Dean Ho, Xavier Tadeo, Cheng Ean Chee, Raghav Sundar, Anh T. L. Truong, Lester W. J. Tan, Benjamin Y. L. Tan, Kirthika Senthil Kumar, Agata Blasiak, Hon Lyn Tan, Nigel Foo, Chong Boon Teo
article en
12 citations

Abstract

In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a patient's own, small dataset to dynamically personalize only their own dose recommendations. The primary objective of this feasibility trial was to assess the logistical and scientific feasibility of providing dynamically personalized AI-derived chemotherapy dose recommendations for patients with advanced solid tumors at/for treatment with single-agent capecitabine, capecitabine in combination with oxaliplatin (XELOX), or capecitabine in combination with irinotecan (XELIRI). CURATE.AI demonstrated adaptability to clinically relevant situations encountered by patients often treated with palliative intent of care. High rates of user adherence were demonstrated, which could be in part due to the high engagement of the physicians in selecting data and boundaries for CURATE.AI operations.

npj Precision OncologyVol. 9(1)
National University of Singapore (SG), National University Cancer Institute, Singapore (SG), National Cancer Centre Singapore (SG), National University Health System (SG)
Ministry of Health -Singapore, National University of Singapore, National Research Foundation Singapore, Ministry of Education - Singapore, National Medical Research Council
Openalex Percentile: Top 0%
Advanced Radiotherapy Techniques
22.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.